On October 9, 2014 Vernalis plc reported that it has licensed worldwide rights in vipadenant (V2006), a small molecule A2A receptor antagonist, to RedoxTherapies Inc (Redox) (Press release, Vernalis, OCT 9, 2014, View Source [SID:1234513891]). Vipadenant has the potential to disrupt an immunosuppressive mechanism of tumor protection, generating improved efficacy for immunotherapies of certain cancers when used in combination.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Redox is a private, Boston-based start-up company that is the exclusive licensee of National Institute of Health (USA) intellectual property in the field of using extracellular adenosine receptor inhibitors in combination with immuno-oncology therapies.

The detailed financial terms of the Licence Agreement with Redox are not disclosed, but Vernalis can earn milestones and royalties on successful clinical, regulatory and commercial advancement.

Commenting on the new relationship, Ian Garland, CEO of Vernalis said "We look forward to having Redox as a partner and to the progress of vipadenant into clinical studies in this exciting new setting for the potential benefit of cancer patients worldwide".